1079396-32-9

Upstream product

• 1079396-09-0 benzyl 4-(4-(2-fluoro-4-(methylsulfonyl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 

Downstream Products

• 1079396-13-6 1-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-N-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo [3,4-d]pyrimidin-4-amine 
• 1079396-14-7 N-(2-fluoro-4-(methylsulfonyl)phenyl)-1-(1-(5-propylpyrimidin-2-yl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1079396-10-3 4-[4-(2-fluoro-4-methanesulfonyl-phenylamino)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidine-1-carboxylic acid isopropyl ester 
• 1079396-11-4 N-(2-fluoro-4-(methylsulfonyl)phenyl)-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

[6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n2, n3, n4, A, B, D, E, G, J, Y, R1 and R2 are defined herein.